Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells

Barlow, Sarah, Brooke, Gary, Chatterjee, Konica, Price, Gareth, Pelekanos, Rebecca, Rossetti, Tony, Doody, Marylou, Venter, Deon, Pain, Scott, Gilshenan, Kristen and Atkinson, Kerry (2008) Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells and Development, 17 6: 1095-1107. doi:10.1089/scd.2007.0154

Author Barlow, Sarah
Brooke, Gary
Chatterjee, Konica
Price, Gareth
Pelekanos, Rebecca
Rossetti, Tony
Doody, Marylou
Venter, Deon
Pain, Scott
Gilshenan, Kristen
Atkinson, Kerry
Title Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells
Journal name Stem Cells and Development   Check publisher's open access policy
ISSN 1547-3287
Publication date 2008-12-08
Year available 2008
Sub-type Article (original research)
DOI 10.1089/scd.2007.0154
Volume 17
Issue 6
Start page 1095
End page 1107
Total pages 13
Place of publication New Rochelle, NY, USA
Publisher Mary Ann Leibert Inc
Collection year 2009
Language eng
Subject C1
970111 Expanding Knowledge in the Medical and Health Sciences
119999 Medical and Health Sciences not elsewhere classified
Abstract Bone marrow is the traditional source of human multipotent mesenchymal stem cells (MSCs), but placenta appears to be an alternative and more readily available source. This study comprehensively compared human placenta-derived MSC (hpMSC) and human bone marrow-derived MSC (hbmMSC) in terms of cell characteristics, optimal growth conditions and in vivo safety specifically to determine if hpMSC could represent a source of human MSC for clinical trial. MSC were isolated from human placenta (hpMSC) and human bone marrow (hbmMSC) and expanded ex vivo using good manufacturing practice-compliant reagents. hpMSC and hbmMSC showed similar proliferation characteristics in different basal culture media types, fetal calf serum (FCS) concentrations, FCS heat-inactivation experiments, flask types and media replacement responsiveness. However, hpMSC and hbmMSC differed with respect to their proliferation capabilities at different seeding densities, with hbmMSC proliferating more slowly than hpMSC in every experiment. hpMSC had greater long-term growth ability than hbmMSC. MSC from both sources exhibited similar light microscopy morphology, size, cell surface phenotype, and mesodermal differentiation ability with the exception that hpMSC consistently appeared less able to differentiate to the adipogenic lineage. A comparison of both hbmMSC and hpMSC from early and medium passage cultures using single-nucleotide polymorphism (SNP) GeneChip analysis confirmed GTG-banding data that no copy number changes had been acquired during sequential passaging. In three of three informative cases (in which the gender of the delivered baby was male), hpMSC were of maternal origin. Neither hpMSC nor hbmMSC caused any acute toxicity in normal mice when injected intravenously at the same, or higher, doses than those currently used in clinical trials of hbmMSC. This study suggests that human placenta is an acceptable alternative source for human MSC and their use is currently being evaluated in clinical trials.
Keyword Umbilical-cord blood
Systemic infusion
Progenitor cells
Term placenta
Stromal cells
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2009 Higher Education Research Data Collection
Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 146 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 163 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 06 Apr 2009, 14:05:29 EST by Joanne PRESTON on behalf of Faculty Of Health Sciences